


Jacques BARTHOLEYNS et al.

attached pages are captioned "VERSION WITH MARKINGS TO SHOW  
CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By   
Benoit Castel  
Attorney for Applicants  
Registration No. 35,041  
745 South 23rd Street  
Arlington, VA 22202  
Telephone: 703/521-2297

December 10, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. Molecular complex according to ~~anyone of claims 1 to 3~~ claim 1, wherein the tissue extract comprises macroscopic fragments or killed or irradiated or haptenized human or animal tumor cells such as lysates or apoptotic bodies, or killed pathogens, such as viruses or bacteria.

6. Molecular complex according to ~~anyone of claims 1 to 3~~ claim 1, wherein the tissue extract comprises normal tissue parts such as tissue membranes, tissue factors, tissue proteins, macroscopic fragments of tissue such as lysates or apoptotic bodies, said tissue being originating from any part of human or animal body or cellular extracts thereof, in particular from thymus, lung, pancreas, cartilage, endothelium, neuromuscular junctions, prostate, sexual organs, bladder, muscles, peripheral nerves, CNS extracts, spleen, liver, bone, heart, skin cells.

8. Molecular complex according to ~~anyone of claims 1 to 7~~ claim 1, wherein the monocyte derived cells recognized by said molecular complex are macrophages, dendritic cells, or antigen presenting cells.

9. Monocyte derived cells such as prepared according to a process comprising the step of contacting monocyte derived cells with a molecular complex according to ~~anyone of claims 1 to 8~~ claim 1.

10. Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to ~~anyone of claims 1 to 5~~ claim 1, under conditions enabling phagocytosis of said molecular complex by said monocyte derived cells, intracellular degradation and processing of the known and unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells together with MHC I and MHC II molecules.

11. Monocyte derived cells such as prepared according to a process comprising contacting monocyte derived cells with a molecular complex according to ~~any one of claims 1 to 3, 6 and 7~~ claim 1, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

12. *Ex vivo* method for stimulating cellular and/or humoral immune responses against unknown components of a tumor tissue extract comprising contacting monocyte derived cells with a molecular complex according to ~~anyone of claims 1 to 5~~ claim 1, under conditions enabling phagocytosis of said molecular complex by monocyte derived cells, intracellular degradation and processing of the known and of unknown components of the tumor tissue extract and the presentation of said known and unknown components on the peripheral membrane of the monocyte derived cells, together with MHC I and II molecules.

13. Method of inducing *in vivo* specific cellular and/or humoral immune responses against unknown components of

tumor tissue extract comprising injections of a molecular complex according to ~~anyone of claims 1 to 5~~ claim 1, for instance by intramuscular, subcutaneous, local or intravenous route.

14. Method of inducing *in vivo* specific cellular and/or humoral responses against unknown components of a tumor tissue extract, comprising sequential and/or simultaneous injections of monocyte derived cells presenting known and unknown components of said tumor tissue extract, together with MHC I and II molecules, as defined in claim 12, and of molecular complexes ~~according to anyone of claims 1 to 5~~.

15. Method for conditioning *ex vivo* human monocytes derived cells, and preferentially macrophages, for them to acquire tissue specificity, comprising contacting monocyte derived cells with a molecular complex according to ~~anyone of claims 1 to 3, or 6 and 7~~ claim 1, under conditions enabling phagocytosis of such molecular complex by the monocyte derived cells.

16. Method of treatment of diseases involving accumulation of conditioned monocyte derived cells according to claim 15 in specific tissue to induce tissue repair and/or regeneration comprising:

- either simultaneous and/or sequential injections of monocyte derived cells and of a molecular complex ~~according to anyone of claims 1 to 3, or 6 and 7~~, under conditions enabling phagocytosis,

- or injection of the monocyte derived cells which have previously phagocytosed a molecular complex ~~according to anyone of claims 1 to 3 or 6 and 7.~~